U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility

Oxford BioMedica says the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to its new biomanufacturing facility in Yarnton, Oxford, to manufacture bulk drug material for Investigational Medicinal Products. The company said with the new facility in operation it will have double the capacity. The company expects capacity expansion at its other site in Oxford to be complete in the first half of this year. Release

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.